LINC01587

Across TCGA pan-cancer cohorts, LINC01587 RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated LINC01587 data layer compared with 4 for mass-spec protein.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher LINC01587 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LINC01587 expression acts as an unfavorable survival marker, although some lineages such as KIRP and KIRC show a favorable association.

CHOL, LIHC, and MESO are the cancer types where LINC01587 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	OS	Quartile	All	0.312	0.847	.001	52	view →
LIHC	OS	Quartile	All	0.412	0.682	.003	35	view →
MESO	OS	Median	IV	0.267	0.815	<.001	30	view →
KIRP	OS	Tertile	All	0.945	0.503	.001	28	view →
LGG	OS	Quartile	All	0.812	0.934	<.001	24	view →
KIRC	DFS	Quartile	III,IV	0.881	0.665	.009	21	view →
READ	OS	Tertile	II,III,IV	1.000	0.539	.020	18	view →
BRCA	DFS	Median	All	0.885	0.918	.018	17	view →
ESCA	DFS	Tertile	II,III,IV	0.851	0.205	.013	16	view →
PCPG	DFS	Median	All	0.953	0.808	.003	14	view →
ACC	DFS	Tertile	All	0.457	0.758	.009	13	view →
BLCA	DFS	Median	All	0.241	0.453	.025	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

LINC01587–CHOL (OS)

Open the CHOL breakdown →